The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.

BACKGROUND AND AIM The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive. METHODS A mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non-MAFLD subjects with advanced liver disease. RESULTS Two thousand two hundred and forty-two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti-HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non-viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7-6.0, P < 0.001), male sex (OR/CI: 1.3/1.0-1.7, P = 0.019), anti-HCV seropositivity (OR/CI: 5.9/4.6-7.5, P = 0.019), MAFLD-lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3-5.2, P = 0.005; compared with the non-MAFLD group) and MAFLD-diabetes (OR/CI: 1.5/1.1-2.1, P = 0.008; compared with the non-MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD-lean MS group (OR/CI: 9.1/2.4-34.6, P = 0.001; compared with non-MAFLD group) and MAFLD-DM group (OR/CI: 2.0/1.2-3.2, P = 0.004; compared with non-MAFLD group). CONCLUSIONS MAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non-viral hepatitis subjects in a community level.

[1]  Ming‐Lung Yu,et al.  Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease , 2023, Journal of clinical and translational hepatology.

[2]  Ming‐Lung Yu,et al.  A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic , 2023, Journal of Microbiology, Immunology and Infection.

[3]  S. Ohnishi,et al.  Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight , 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  V. de Lédinghen,et al.  Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study) , 2023, Hepatology.

[5]  C. Liu,et al.  Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives , 2023, Clinical and molecular hepatology.

[6]  S. Ahn.  Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments , 2023, Clinical and molecular hepatology.

[7]  J. Yu,et al.  Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future , 2022, Clinical and molecular hepatology.

[8]  L. Castéra,et al.  Identification of high-risk subjects in nonalcoholic fatty liver disease , 2022, Clinical and molecular hepatology.

[9]  C. Byrne,et al.  Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future , 2022, Clinical and molecular hepatology.

[10]  I. Waked,et al.  Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study , 2022, Alimentary pharmacology & therapeutics.

[11]  M. Yuen,et al.  Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis , 2022, Hepatology.

[12]  Ming‐Lung Yu,et al.  Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes , 2022, The Kaohsiung journal of medical sciences.

[13]  M. Vacca,et al.  Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. , 2022, Journal of hepatology.

[14]  M. Yuen,et al.  On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Ming‐Lung Yu,et al.  The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments , 2021, Biomedicines.

[16]  V. Wong,et al.  Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. , 2021, The Journal of infectious diseases.

[17]  J. Lazarus,et al.  MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective , 2021, Alimentary pharmacology & therapeutics.

[18]  Ming‐Lung Yu,et al.  Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan , 2021, BMJ Open.

[19]  Shigui Yang,et al.  Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis , 2021, Annals of translational medicine.

[20]  Hwai I. Yang,et al.  Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B. , 2020, The Journal of infectious diseases.

[21]  P. Lampertico,et al.  Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs , 2020, Hepatology.

[22]  W. Lai,et al.  Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication , 2020, The Kaohsiung journal of medical sciences.

[23]  S. Friedman,et al.  Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis , 2020, Hepatology communications.

[24]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[25]  G. Marchesini,et al.  Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation , 2020, Hepatology.

[26]  M. Manns,et al.  Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) , 2019, Zeitschrift für Gastroenterologie.

[27]  R. Hultcrantz,et al.  Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study , 2017, Hepatology communications.

[28]  Ming‐Lung Yu,et al.  The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon‐free direct antiviral agents , 2017, The Kaohsiung journal of medical sciences.

[29]  D. Consonni,et al.  Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  G. Papatheodoridis,et al.  Non-alcoholic fatty liver disease may develop in individuals with normal body mass index , 2012, Annals of gastroenterology.

[31]  H. Cortez‐Pinto,et al.  Hepatic steatosis in hepatitis B virus infected patients: Meta‐analysis of risk factors and comparison with hepatitis C infected patients , 2011, Journal of gastroenterology and hepatology.

[32]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[33]  Yoshiyuki Suzuki,et al.  Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C , 2009, Hepatology.

[34]  T. Asselah,et al.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.

[35]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.